Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | PGK2 | P07205 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | LAP3 | P28838 | 3/20 | 0.33 |
| ▸ | PGD | P52209 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26229066 | 0.78 | P2RY10 (0.40) | — | |
| SCHEMBL18501623 | 0.78 | P2RY10 (0.40) | — | |
| SCHEMBL21219402 | 0.77 | MAPK1 (0.34) | PGK1PGK2 | |
| SCHEMBL15601926 | 0.77 | PGK1 (0.59) | PGK1PGK2LAP3PGD | |
| SCHEMBL14241195 | 0.77 | PGK1 (0.59) | PGK1PGK2LAP3PGD | |
| SCHEMBL14439802 | 0.74 | LMNA (0.31) | — | |
| SCHEMBL26393533 | 0.72 | — | — | |
| SCHEMBL2984742 | 0.71 | GABRR1 (0.37) | GABRR1CYP1A2LAP3 | |
| SCHEMBL11933048 | 0.71 | — | — | |
| SCHEMBL143520 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348907-A1 | OLIGONUCLEOTIDES FOR MECP2 MODULATION | UNIVERSITY OF MASSACHUSETTS | 2023-11-02 | — | — | US | disclosed |
| US-20230340475-A1 | OLIGONUCLEOTIDES FOR MLH1 MODULATION | UNIV MASSACHUSETTS (US) | 2023-10-26 | — | — | US | disclosed |
| US-20170043024-A1 | BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY | UNIVERSITY OF MASSACHUSETTS | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340475-A1 | OLIGONUCLEOTIDES FOR MLH1 MODULATION | MSH2, MSH6, PMS2 | PGK1 3335/4885PGK2 3217/4885LTA4H 4250/4885 |
| US-20170043024-A1 | BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY | DCLRE1B, RTCB, RNASE1 | PGK1 4290/4885PGK2 3977/4885LTA4H 2354/4885 |
| US-20230348907-A1 | OLIGONUCLEOTIDES FOR MECP2 MODULATION | MECP2, TARDBP, SMN1; SMN2 | PGK1 4003/4885PGK2 3643/4885LTA4H 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.